SYK Stryker Corp

Kalamazoo, Michigan - August 1, 2014 - Stryker Corporation (NYSE:SYK) announced today the completion of its acquisition of substantially all of the North American assets of Small Bone Innovations, Inc. ("SBi"). A separate closing will be held later this year, following receipt of applicable regulatory approvals, for the acquisition of the assets of the French and German operations, through which the international business of SBi has been conducted.

SBi is a privately held business headquartered in Morrisville, Pennsylvania that was founded by Viscogliosi Brothers, LLC. SBi products are designed and promoted for upper and lower extremity small bone indications, with a focus on small joint replacement. The assets to be acquired include the Scandinavian Total Ankle Replacement System (STAR Ankle). The STAR Ankle is the only PMA approved, cementless, three-piece total ankle replacement system and is the most published total ankle replacement product in the world. With the addition of the STAR Ankle to the Stryker Foot & Ankle product portfolio, Stryker comprehensively addresses the broad range of foot and ankle procedures. Additional assets include finger, wrist, and elbow products, further expanding the existing Stryker upper extremity product offerings.

Stryker is one of the world's leading medical technology companies and together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. Stryker products and services are available in over 100 countries around the world. Please contact us for more information at www.stryker.com.

Contacts

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com

Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker (NYSE:SYK)
Historical Stock Chart
From Aug 2024 to Sep 2024

Stryker (NYSE:SYK)
Historical Stock Chart
From Sep 2023 to Sep 2024